Live from ASH 2024 | Oral Report Features Encouraging Data of Ascentage Pharma’s Bcl-2 Inhibitor Lisaftoclax in R/R MM, Including a Median PFS Over 9 Months
ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released the latest clinical data of its novel Bcl-2 selective inhibitor, lisaftoclax (APG-2575), in...
Live from ASH 2024 | Ascentage Pharma Releases Updated Data of Bcl-2 Inhibitor Lisaftoclax in MDS that Demonstrates Potential Clinical Benefits and Favorable Safety
ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released the follow-up safety and efficacy data of the company's investigational Bcl-2 selective inhibitor,...
Live from ASH 2024 | 1.5-Year Follow-Up Data from a Global Study of Olverembatinib Reaffirms Potential in Overcoming Resistance/Intolerance to Ponatinib or Asciminib
ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released the latest clinical data from a global study of its novel drug candidate,...
Live from ASH 2024 | Ascentage Pharma’s Bcl-2 Inhibitor Lisaftoclax in Combinations Demonstrates Potential Clinical Benefit in Patients with Prior Exposure to Venetoclax
ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released the latest clinical data of lisaftoclax (APG-2575) as a monotherapy or in combinations in...
Live from ASH 2024 | First Dataset of Olverembatinib as Second-Line Therapy in Patients with Non-T315I-Mutant CP-CML Presented in Oral Report
ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that Prof. Weiming Li, of Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, has...
Terumo Health Outcomes and Medis Medical Imaging Announce Strategic Partnership to Enhance Cardiovascular Care
– Collaboration combines Terumo's ePRISM™ precision medicine software platform with Medis' QFR® technology – SOMERSET, N.J., Dec. 10, 2024 /PRNewswire/ -- Terumo Health Outcomes (THO), a division of Terumo Interventional Systems (TIS), and Medis Medical Imaging, a leading cardiac imaging software company, announced today that they have entered into a strategic partnership, in...
Live from ASH 2024 | First Dataset of Olverembatinib in Combination with Bcl-2 Inhibitor Lisaftoclax Demonstrates Potential Clinical Benefits as a Chemotherapy-Free Regimen for Children with R/R Ph+ ALL
ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released the safety and efficacy data of the company's novel drug candidate, olverembatinib (HQP1351),...
Introducing the Gianna Lullume Smart Infant Sleep Device: A Revolutionary Solution for Infant Sleep Now on Kickstarter
HONG KONG, Dec. 10, 2024 /PRNewswire/ -- The Gianna Lullume Smart Infant Sleep Device, an innovative product developed by Kerchan Group, has officially launched on Kickstarter. This innovative sleep aid for infants boasts cutting-edge technology and a user-friendly interface, quickly gaining interest from parents worldwide. Designed specifically for infants, this smart sleep device leverages advanced features including intelligent cry detection,...
Syntara announces positive interim data in Phase 2 study of SNT-5505 in myelofibrosis
SYDNEY, Dec. 10, 2024 /PRNewswire/ -- Syntara Limited (ASX:SNT), a clinical-stage drug development company, is pleased to announce positive interim data from its ongoing Phase 2 clinical trial evaluating SNT-5505 (200 mg BID) in combination with ruxolitinib (RUX) for the treatment of myelofibrosis (MF)1. The interim results2 suggest that SNT-5505 has potential as a breakthrough therapy for MF and...
PENTAX Medical obtained US FDA 510(k) clearance for new models of the PENTAX Medical i20c Video Endoscope Series
MONTVALE, N.J., Dec. 10, 2024 /PRNewswire/ -- PENTAX Medical, a division of HOYA Group, has obtained US FDA 510(k) clearance for new models of the PENTAX Medical i20c Video Endoscope Series—PENTAX Medical Video Colonoscope EC34-i20cL, PENTAX Medical Video Upper GI Scope EG27‑i20c and Right/Left Wheel Extender OE-B17. The PENTAX Medical i20c Video...
